The dispute involves provisions of the Patent Act that “bar” an inventor from obtaining a patent if the inventor publicizes the invention or exploits it commercially before filing an application. Based on the Justice's comments taken from the transcript of the oral argument, which largely favored Teva, it is highly likely that the decision by the Federal Circuit, holding that an inventor puts an invention “on sale,” will be upheld. Thus the inventor loses a right to patent it, upon any sale, public or private.
top of page
Search
Recent Posts
See AllBy way of highlighting what was not done in this case to show a good cause for submitting new evidence, the Board provides guidance...
50
Endo Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, INC. (CAFC; 28-March-2019) This case is an appeal from the United States District...
50
Forest Laboratories v. Sigmapharm Laboratories, LLC (CAFC; 14-Mar-2019) (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders...
10
bottom of page
Comments